The British Journal of Cardiology

This site is intended for UK healthcare professionals

 
BJC_tv_logo_white
Sign in
Promotional video developed and funded by Pfizer Ltd intended for UK HCPs only.
Vyndaqel®▼ (tafamidis) prescribing information is available here. Adverse events reporting information can be found at the bottom of the page.
Pfizer 100px

Exploring cardiac amyloidosis: Diagnosis, treatment, and best practices

31 March 2026
Job code: PP-VYN-GBR-3195 | April 2026

Sponsored

Studies report up to 18% (n/N = 9/49) of patients aged ≥60 years old with heart failure with preserved ejection fraction (HFpEF) had transthyretin amyloid cardiomyopathy (ATTR-CM), one of the main types of cardiac amyloidosis.1 Clinical expert Dr Kate Gatenby highlights this and gives an overview of the causes, diagnosis and best practices in the management of patients with ATTR-CM.
Reference
  1. Bennani SY et al. Int J Cardiovasc Imaging 2016;32:1403–13

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to Pfizer Medical information on 01304 616161.

Categories

Tags

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.

BJC TV

To continue, please confirm that you are a UK healthcare professional.

I am not a UK healthcare professional
I confirm I am a UK healthcare professional